Cannabics
Pharmaceuticals today announced that it has attained Good Manufacturing
Practices (GMP) capabilities. Additionally, the company reported it is moving
toward the launch of its first clinical study of Cannabics SR capsules.
GMP
regulations are designed to ensure that products are produced and controlled
according to quality standards. Adhering to these practices ranks Cannabics’
products among a very limited number of medical cannabis products available in
the U.S. market that are manufactured according to GMP standards.
Cannabics’
Chief Technology Officer Dr. Eyal Ballan stated, “We’re proud to announce GMP
standing as we prepare for the upcoming launch of our Cannabics SR capsules. We
have developed a product with incredible potential in the oncology market and
aim to maintain product integrity throughout the entire manufacturing process.”
Cannabics
plans to launch a number of clinical studies in leading medical centers in
Israel where the company’s R&D division is strategically located. The
company is on track to become one of the first and few companies to commercialize
clinically tested cannabis-based products.
“Cannabics
SR, our first market ready product, was developed and designed specifically as
a palliative therapy for oncology patients,” commented Dr. Ballan. “We are
still developing a broad pipeline of additional cannabis based products
designed for various indications such as Neuropathic pain, inflammatory bowel
disease, post trauma stress syndrome, CNS degenerative disorders and more. Each
of these products will be tested in comprehensive and formal clinical studies
to prove its efficacy and safety.”
Cannabics
emphasized that its products will have a strong advantage over competing
medical cannabis products in the market. In addition to the superior
pharmacokinetic profile of the Cannabics SR formulations, the company will have
clinical results of the efficacy and safety data collected in these formal
post-marketing studies.
Cannabics
intends to market Cannabics SR capsules under the current medical cannabis
regulations in the United States, Europe and Israel. Based on a proprietary
formulation that contains only certified food ingredients, Cannabics SR
capsules will be marketed as a “cannabis-infused edible product” and will be
available to certified and registered patients.
In
previous observational studies, Cannabics SR capsules has been shown to provide
10-12 hours of reduced nausea and pain while promoting appetite for cancer
patients. These capsules are taken only one to two times a day. Also, because
they are taken orally as capsules, patients avoid the long-term harmful effects
of smoking cannabis.
“Cannabics
SR capsules answer a considerable unmet need to alleviate the discomforts of
oncology patients without the health hazards associated with smoking cannabis
for palliative purpose,” stated Dr. Ballan. “To date, more than 100 patients in
Israel (most of them oncology patients) have already been treated with
Cannabics SR capsules. The positive responses and high satisfaction level of
patients and doctors with this cannabis based therapy option has been
overwhelming.”
For
more information, visit www.cannabics.com
About QualityStocks
QualityStocks
is committed to connecting subscribers with companies that have huge potential
to succeed in the short and long-term future. We offer several ways for
investors to find, evaluate, and learn more about investing in these companies.
Sign
up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net
The
Quality Stocks Daily Blog http://blog.qualitystocks.net
The
Quality Stocks Daily Videos http://videocharts.qualitystocks.net
The
Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net
Please
see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net
No comments:
Post a Comment